Mediwound Ltd (MDWD) was Initiated by Aegis Capital to “Buy” and the brokerage firm has set the Price Target at $11. Aegis Capital advised their investors in a research report released on Nov 28, 2016.
On the company’s financial health, Mediwound Ltd reported $-0.26 EPS for the quarter, based on the information available during the earnings call on Nov 14, 2016. Analyst had a consensus estimate of $-0.26. The company had revenue of $.52 million for the quarter, compared to analysts expectations of $.61 million. The company’s revenue was up 420.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.
Mediwound Ltd opened for trading at $5.05 and hit $5.25 on the upside on Friday, eventually ending the session at $5.25, with a gain of 5.00% or 0.25 points. The heightened volatility saw the trading volume jump to 2,544 shares. Company has a market cap of $115 M.
MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing manufacturing and commercializing products to address unmet needs in the fields of severe burns chronic and other hard-to-heal wounds and connective tissue disorders. The Companys biopharmaceutical product NexoBrid which is based on its patented proteolytic enzyme technology represents a new paradigm in burn care management and its clinical trials have demonstrated with statistical significance its ability to non-surgically and rapidly remove the eschar earlier upon patient admission without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.